The evolution of V.A.C.® Therapy

One unit, three therapies*

V.A.C. Ultra™ Negative Pressure Wound Therapy System
- V.A.C.® Negative Pressure Wound Therapy
- V.A.C. VeraFlo™ Instillation Therapy
- ABThera™ Open Abdomen Negative Pressure Therapy

*when used with the appropriate dressings†
Enhanced Graphic User Interface
Intuitive touch screen menu with fewer screens to initiate therapy

Simple therapeutic programming

Customized Pressure Algorithms
Continuous negative pressure (from -25 to -200mmHg)

Dynamic Pressure Control is the evolution of intermittent therapy that maintains minimum negative pressure levels between cycles, helping to prevent leaks and fluid accumulation that can occur when there is no negative pressure at the wound site

Proven V.A.C.® Therapy System
Compatible for use with existing V.A.C.® Therapy System accessories:

**SensaT.R.A.C.™ Technology** provides continuous feedback for enhanced negative pressure accuracy.

**V.A.C.® GranuFoam™** Dressings help promote granulation tissue formation and facilitate exudate removal.

**V.A.C.® Canisters** collect exudate.

**Seal Check™ Leak Detector** offers instant feedback to help identify leaks.
Choose V.A.C.® Therapy

PROVEN BENEFITS

Effective Healing
Mechanism of action promotes granulation tissue formation while providing a closed, moist wound healing environment.

Clinically Proven
V.A.C.® Therapy is the only negative pressure technology substantiated by more than 40 randomized, controlled, clinical trials and over 825 peer-reviewed articles.*

Cost-effective
In published studies on a variety of wound types, V.A.C.® Therapy has demonstrated the potential to help reduce:
- Length of stay¹-⁴
- Readmissions¹,⁵
- Need for surgeries¹,⁶

*As of September 2013

V.A.C.® Therapy promotes wound healing through well-established mechanisms of action.

**Macrostrain:**
- Decreases wound margins
- Removes exudate
- Reduces edema
- Removes infectious material

**Microstrain**:⁷⁻¹⁰
Promotes granulation tissue formation and perfusion by means of:
- Cell proliferation
- Fibroblast migration
Choose **V.A.C. VeraFlo™ Therapy**

ADDITIONAL THERAPEUTIC BENEFITS

V.A.C. VeraFlo™ Therapy is for wounds that would benefit from instillation therapy, such as:

- **Contaminated** wounds with instillation of topical wound cleansers.
- **Infected wounds** with instillation of appropriate topical wound solutions; these wounds also benefit from the removal of infectious materials in the V.A.C.® Therapy cycle.

**Bench and preclinical studies:**

- **In a bench top study evaluating the potential for cross contamination:** V.A.C. VeraFlo™ Therapy provided contained controlled wound irrigation without bacterial aerosolization. Standard manual cleansing techniques demonstrated significant bacterial aerosolization 6 inches from the simulated wound site (p<0.05).¹²

- **In a porcine study with saline instillation:** 7 days of V.A.C. VeraFlo™ Therapy using V.A.C. VeraFlo™ Dressings showed a 43% increase in wound fill compared to NPWT using V.A.C.® GranuFoam™ Dressings (p<0.05). V.A.C. VeraFlo™ Therapy cycles utilized a 5-minute soak time followed by 2.5 hours of V.A.C.® Therapy.¹¹

  These results have not yet been confirmed in human studies.

**V.A.C. VeraFlo™ Therapy provides:**

**Volumetric Delivery**
With a pump for automated delivery of topical wound solutions.

**Fill Assist**
Helps determine the correct instill volume.

**Dressing Soak**
Instills topical wound solutions into the wound for easier dressing removal and increased patient comfort.

**V.A.C. VeraFlo™ Therapy** combines the benefits of V.A.C.® Therapy with automated solution distribution and removal.

V.A.C. VeraFlo™ Therapy can:

- **Cleanse**
  the wound with instillation of topical wound cleansers in a consistent, controlled manner

- **Treat**
  the wound with the instillation of appropriate topical antimicrobial and antiseptic solutions and the removal of infectious material

- **Heal**
  the wound and prepare for primary or secondary closure
V.A.C. Ultra™ Therapy Accessories
WITH ALL THE RIGHT PIECES

V.A.C. VeraT.R.A.C.” Technology
Enhancement of SensaT.R.A.C.” Technology for delivery of negative pressure wound therapy, as well as delivery and removal of topical wound solutions.

V.A.C. VeraT.R.A.C.™ Pad
Delivery and removal through a single pad.

V.A.C. VeraT.R.A.C. Duo™ Tube Set
Delivery and removal through separate pads.

V.A.C. VeraLink™ Cassette
Holds and delivers user-provided wound solutions.

V.A.C. VeraFlo™ Dressings
Provide even distribution of wound solutions across the wound bed.

V.A.C. VeraFlo™ Dressing
Promotes granulation tissue formation and is appropriate for wounds when using V.A.C. VeraFlo™ Therapy.

V.A.C. VeraFlo Cleanse™ Dressing
Allows clinicians flexibility in addressing wounds with complex geometries and is appropriate for wounds when using V.A.C. VeraFlo™ Therapy.

<table>
<thead>
<tr>
<th>Dressing Property</th>
<th>V.A.C.® GranuFoam™ Dressing</th>
<th>V.A.C.® WhiteFoam Dressing</th>
<th>V.A.C. VeraFlo™ Dressing</th>
<th>V.A.C. VeraFlo Cleanse™ Dressing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Material</td>
<td>Black Polyurethane ether</td>
<td>White Polyvinyl alcohol</td>
<td>Black Polyurethane ester</td>
<td>Grey Polyurethane ester</td>
</tr>
<tr>
<td>Open cell reticulated</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Pore size</td>
<td>400-600 microns all directions</td>
<td>60-270 microns</td>
<td>400-600 microns</td>
<td>133-600 microns depends on direction</td>
</tr>
<tr>
<td>Relative hydrophobicity*</td>
<td>1</td>
<td>4</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>(lowest value = highest level of hydrophobicity)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shape</td>
<td>Variable shapes/sizes</td>
<td>Sheets</td>
<td>V.A.C. VeraFlo™ Sm &amp; Med: Spiral cut sheet</td>
<td>Rod with center perforations for ease of separation into halves</td>
</tr>
<tr>
<td>Tensile strength - Dry</td>
<td>Baseline</td>
<td>3 times greater than baseline</td>
<td>1.7 times greater than baseline</td>
<td>2.5 times greater than V.A.C. VeraFlo™ Dressing dry</td>
</tr>
<tr>
<td>Tensile strength - Wet</td>
<td>Baseline</td>
<td>3.7 times greater than baseline</td>
<td>1.5 times greater than baseline</td>
<td>3 times greater than V.A.C. VeraFlo™ Dressing wet</td>
</tr>
<tr>
<td>7 day granulation tissue formation** (Swine model data)***</td>
<td>Baseline</td>
<td>20% less than baseline</td>
<td>43% greater than baseline</td>
<td></td>
</tr>
</tbody>
</table>

Therapy Applied

<table>
<thead>
<tr>
<th>Therapy Applied</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>V.A.C.® Therapy</td>
<td>37% greater than V.A.C.® WhiteFoam Dressing with V.A.C.® Therapy</td>
</tr>
<tr>
<td>V.A.C.® Therapy (Saline)</td>
<td>24% less than V.A.C. VeraFlo™ Therapy</td>
</tr>
<tr>
<td>V.A.C. VeraFlo™ Therapy (Saline)</td>
<td>43% greater than baseline</td>
</tr>
</tbody>
</table>

*Lowest value = highest level of hydrophobicity.
**Granulation thickness based on histology; results have not yet been confirmed in human studies.

V.A.C. Ultra™ Therapy Accessories
WITH ALL THE RIGHT PIECES

V.A.C. VeraT.R.A.C.” Technology
Enhancement of SensaT.R.A.C.” Technology for delivery of negative pressure wound therapy, as well as delivery and removal of topical wound solutions.

V.A.C. VeraT.R.A.C.™ Pad
Delivery and removal through a single pad.

V.A.C. VeraT.R.A.C. Duo™ Tube Set
Delivery and removal through separate pads.

V.A.C. VeraLink™ Cassette
Holds and delivers user-provided wound solutions.

V.A.C. VeraFlo™ Dressings
Provide even distribution of wound solutions across the wound bed.

V.A.C. VeraFlo™ Dressing
Promotes granulation tissue formation and is appropriate for wounds when using V.A.C. VeraFlo™ Therapy.

V.A.C. VeraFlo Cleanse™ Dressing
Allows clinicians flexibility in addressing wounds with complex geometries and is appropriate for wounds when using V.A.C. VeraFlo™ Therapy.

<table>
<thead>
<tr>
<th>Dressing Property</th>
<th>V.A.C.® GranuFoam™ Dressing</th>
<th>V.A.C.® WhiteFoam Dressing</th>
<th>V.A.C. VeraFlo™ Dressing</th>
<th>V.A.C. VeraFlo Cleanse™ Dressing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Material</td>
<td>Black Polyurethane ether</td>
<td>White Polyvinyl alcohol</td>
<td>Black Polyurethane ester</td>
<td>Grey Polyurethane ester</td>
</tr>
<tr>
<td>Open cell reticulated</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Pore size</td>
<td>400-600 microns all directions</td>
<td>60-270 microns</td>
<td>400-600 microns</td>
<td>133-600 microns depends on direction</td>
</tr>
<tr>
<td>Relative hydrophobicity*</td>
<td>1</td>
<td>4</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>(lowest value = highest level of hydrophobicity)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shape</td>
<td>Variable shapes/sizes</td>
<td>Sheets</td>
<td>V.A.C. VeraFlo™ Sm &amp; Med: Spiral cut sheet</td>
<td>Rod with center perforations for ease of separation into halves</td>
</tr>
<tr>
<td>Tensile strength - Dry</td>
<td>Baseline</td>
<td>3 times greater than baseline</td>
<td>1.7 times greater than baseline</td>
<td>2.5 times greater than V.A.C. VeraFlo™ Dressing dry</td>
</tr>
<tr>
<td>Tensile strength - Wet</td>
<td>Baseline</td>
<td>3.7 times greater than baseline</td>
<td>1.5 times greater than baseline</td>
<td>3 times greater than V.A.C. VeraFlo™ Dressing wet</td>
</tr>
<tr>
<td>7 day granulation tissue formation** (Swine model data)***</td>
<td>Baseline</td>
<td>20% less than baseline</td>
<td>43% greater than baseline</td>
<td></td>
</tr>
</tbody>
</table>

Therapy Applied

<table>
<thead>
<tr>
<th>Therapy Applied</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>V.A.C.® Therapy</td>
<td>37% greater than V.A.C.® WhiteFoam Dressing with V.A.C.® Therapy</td>
</tr>
<tr>
<td>V.A.C.® Therapy (Saline)</td>
<td>24% less than V.A.C. VeraFlo™ Therapy</td>
</tr>
<tr>
<td>V.A.C. VeraFlo™ Therapy (Saline)</td>
<td>43% greater than baseline</td>
</tr>
</tbody>
</table>

*Lowest value = highest level of hydrophobicity.
**Granulation thickness based on histology; results have not yet been confirmed in human studies.
When using V.A.C.Ultra™ Therapy Unit for V.A.C.® Therapy only, it is compatible with V.A.C.® Dressings featuring SensaT.R.A.C.™ Technology.

### V.A.C. ULTA™ SYSTEM ORDERING INFORMATION FOR V.A.C. VERAFLOR™ THERAPY

<table>
<thead>
<tr>
<th>Part Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ULTDEV01/US</td>
<td>V.A.C.Ultra™ Therapy Unit, United States</td>
</tr>
<tr>
<td>ULTVFL05SM</td>
<td>V.A.C. VeraFlor™ Dressing, 5-pack, Small</td>
</tr>
<tr>
<td>ULTVFL05MD</td>
<td>V.A.C. VeraFlor™ Dressing, 5-pack, Medium</td>
</tr>
<tr>
<td>ULTVFL05MD</td>
<td>V.A.C. VeraFlor Cleanse™ Dressing, 5-pack, Medium</td>
</tr>
<tr>
<td>ULTVFL05LG</td>
<td>V.A.C. VeraFlor™ Dressing, 5-pack, Large</td>
</tr>
<tr>
<td>ULTINK0500</td>
<td>V.A.C. VeraLink™ Cassette, 5-pack</td>
</tr>
<tr>
<td>ULTDUO0500</td>
<td>V.A.C. VeraT.R.A.C. Duo™ Tube Set, 5-pack</td>
</tr>
<tr>
<td>M8275063/5</td>
<td>500mL InfoV.A.C.® Canister with Gel</td>
</tr>
<tr>
<td>M8275093/5</td>
<td>1000mL InfoV.A.C.® Large Canister with Gel</td>
</tr>
</tbody>
</table>

*V.A.C. Ultra™ Therapy Unit is compatible with all InfoV.A.C.® canisters

† The dressings to be used with each therapy option are: 1) V.A.C.® Therapy using V.A.C.® GranuFoam™ and V.A.C.® WhiteFoam Dressings, 2) V.A.C. VeraFlor™ Instillation Therapy using V.A.C. VeraFlor™ and V.A.C. VeraFlor Cleanse™ Dressings, and 3) ABThera® Open Abdomen Negative Pressure Therapy using ABThera® SensaT.R.A.C.™ Open Abdomen Dressing. Do not use V.A.C. VeraFlor™ Therapy when using the ABThera® SensaT.R.A.C.™ Open Abdomen Dressing. Visit www.openabdomen.com for more information on ABThera® Open Abdomen Negative Pressure Therapy.

For more information about the V.A.C.Ultra™ Therapy System, contact us at 1-800-275-4524 or visit www.vaculta.com.

**NOTE:** Specific indications, contraindications, warnings, precautions and safety information exist for KCI products and therapies. Please consult a physician and product instructions for use prior to application. Rx only.

©2011 KCI Licensing, Inc. All rights reserved. All trademarks designated herein are proprietary to KCI Licensing, Inc., its affiliates and/or licensors. DSL#13-0350.US • LIT 29-A-211 • Rev 10/13